These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36273268)

  • 1. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
    Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
    J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
    Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
    Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
    Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1.
    Lee DS; Lee S; Kim C; Kim D; Kim KP; Yoo C
    Anticancer Res; 2022 Jul; 42(7):3435-3443. PubMed ID: 35790285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2.
    Yadav AK; Jang BC
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
    Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
    Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro.
    Faust RA; Tawfic S; Davis AT; Bubash LA; Ahmed K
    Head Neck; 2000 Jul; 22(4):341-6. PubMed ID: 10862016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
    Chon HJ; Bae KJ; Lee Y; Kim J
    Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
    Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
    Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck.
    Su YW; Lin YH; Pai MH; Lo AC; Lee YC; Fang IC; Lin J; Hsieh RK; Chang YF; Chen CL
    PLoS One; 2014; 9(4):e96183. PubMed ID: 24769813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
    Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
    Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck.
    Gapany M; Faust RA; Tawfic S; Davis A; Adams GL; Ahmed K
    Mol Med; 1995 Sep; 1(6):659-66. PubMed ID: 8529132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
    Rosales M; Rodríguez-Ulloa A; Besada V; Ramón AC; Pérez GV; Ramos Y; Guirola O; González LJ; Zettl K; Wiśniewski JR; Perera Y; Perea SE
    Cells; 2021 Feb; 10(2):. PubMed ID: 33562780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC
    Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2.
    Su YW; Xie TX; Sano D; Myers JN
    PLoS One; 2011 Apr; 6(4):e19412. PubMed ID: 21559372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.